Skip to main content
. 2021 Jul 22;13(8):e12881. doi: 10.15252/emmm.202012881

Figure 3. Detection of ctDNA in plasma, urine, and CSF is affected by intra‐tumor heterogeneity in gliomas.

Figure 3

  • A
    Mutant allele fraction (MAF) measured in tumor, CSF, plasma, and urine samples (on the y axis) for the detected mutations, in the 52 genes that are most frequently mutated in gliomas based on the TCGA databases (on the x‐axis), for the eight patients analyzed by targeted sequencing panels. MAF from tumor is derived from exome sequencing. MAF from CSF, plasma, and urine samples are derived from the capture panels sequencing.
  • B
    Number of mutations detected in tumor samples that were observed across several individual tumor biopsies (shared) or private to an individual biopsy.
  • C–E
    Comparison of the number of mutations that were detected in multiple tumor tissue subparts (red), that were private to an individual subpart (blue), or that were rescued by merged calling (green) in CSF (C), plasma (D), and urine (E). Data are shown for samples collected immediately prior to surgery across all eight patients.